文献速递脊柱关节炎

中轴型脊柱关节炎中多次治疗转换的发生情况:来自五个北欧风湿病注册中心的结果

The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

基于丹麦、瑞典、芬兰、挪威和冰岛五个生物制剂注册中心的观察性队列研究,纳入2009至2018年首次启用生物制剂或靶向合成DMARD的8398例中轴型脊柱关节炎患者。结果显示,2009至2015年启动治疗的患者中,3年随访内使用≥3、≥4、≥5种b/tsDMARD者分别占8%、3%、1%;多药转换的累积发生率无日历时期趋势。与多药转换相关的基线特征包括女性、较短病程、较高患者总体评分、合并症及银屑病,但葡萄膜炎不在其列。

要点

  • 8398例中轴型脊柱关节炎患者中,3年随访内使用≥3种b/tsDMARD者占8%,≥4种者占3%,≥5种者占1%。
  • 多药转换的累积发生率在不同日历时期(2009-2011、2012-2013、2014-2015、2016-2018)之间无变化趋势。
  • 多药转换(≥3种b/tsDMARD)的基线相关因素包括女性、较短病程、较高患者总体评分、合并症及银屑病,而非葡萄膜炎。

核心结论

  • 在这一大型北欧中轴型脊柱关节炎观察性队列中,多次转换频繁发生,且未观察到明显的时间趋势。
  • 临床相关因素包括性别,也包括既往合并症和关节外表现,凸显了治疗该患者群体持续存在的挑战。

研究设计与样本

  • 观察性队列研究,基于五个生物制剂注册中心(丹麦、瑞典、芬兰、挪威、冰岛)2009至2018年首次启用b/tsDMARD的中轴型脊柱关节炎患者数据。
  • 合并症和关节外表现通过链接国家注册中心识别。
  • 多药转换按b/tsDMARD治疗史重叠分类定义:随访期间使用≥3、≥4或≥5种b/tsDMARD。
  • 按日历时期(2009-2011、2012-2013、2014-2015、2016-2018)分层探索使用≥3种b/tsDMARD的多药转换累积发生率。
  • 在2009至2015年首次启用b/tsDMARD的患者亚组中,采用多因素logistic回归分析探索与3年随访内多药转换相关的基线特征。

主要发现

  • 共纳入8398例患者,其中6056例于2009至2015年首次启用b/tsDMARD(63%为男性,中位年龄42岁)。
  • 在2009至2015年启动治疗的患者中,3年随访内使用≥3、≥4或≥5种b/tsDMARD的比例分别为8%、3%和1%。
  • 日历时期不影响多药转换的累积发生率。
  • 与多药转换(≥3种b/tsDMARD)相关的基线特征为女性、较短病程、较高患者总体评分、合并症及患有银屑病,但葡萄膜炎不在其列。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In axial spondyloarthritis (axSpA), switching between multiple biologic or targeted synthetic (b/ts-) DMARDs might indicate difficult-to-treat disease. We aimed to explore the occurrence of multiple switching in routine care axSpA patients using various definitions, and to identify associated clinical characteristics upon start of first b/tsDMARD (baseline). METHODS: Observational cohort study including patients with axSpA starting a first-ever b/tsDMARD 2009-2018 based on data from five biologic registries (Denmark/Sweden/Finland/Norway/Iceland). Comorbidities and extra-articular manifestations were identified through linkage to national registries. Multi-switching was defined in overlapping categories according to b/tsDMARD treatment history: treatment with ≥3, ≥4 or ≥5 b/tsDMARDs during follow-up. We explored the cumulative incidence of patients becoming multi-switchers with ≥3 b/tsDMARDs stratified by calendar-period (2009-2011, 2012-2013, 2014-2015, 2016-2018). In the subgroup of patients starting a first b/tsDMARD 2009-2015, baseline characteristics associated with multi-switching (within 3 years' follow-up) were explored using multiple logistic regression analyses. RESULTS: Among 8398 patients included, 6056 patients (63% male, median age 42 years) started a first b/tsDMARD in 2009-2015, whereof proportions treated with ≥3, ≥4 or ≥5 b/tsDMARDs within 3 years' follow-up were 8%, 3% and 1%, respectively. Calendar-period did not affect the cumulative incidence of multi-switching. Baseline characteristics associated with multi-switching (≥3 b/tsDMARDs) were female gender, shorter disease duration, higher patient global score, comorbidities and having psoriasis but not uveitis. CONCLUSION: In this large Nordic observational cohort of axSpA patients, multiple switching was frequent with no apparent time-trend. Clinical associated factors included gender, but also previous comorbidities and extra-articular manifestations illustrating the ongoing challenge of treating this patient group.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Di Giuseppe D, Lindström U, Aaltonen K, et al. The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology (Oxford). 2022. PMID: 34940795. doi:10.1093/rheumatology/keab946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。